Izolo, iingcali ezivela kwi-FDA (uLawulo lokuTya kunye neDrugs) zihlolisise imeko ye-IQOS, inkqubo yecuba edumileyo kaPhilip Morris. Kwaye kuninzi ukuthetha ukuba i-FDA ayizange ithandabuze ukuthatha isigqibo kwindawo apho ichaza ukuba uPhilip Morris akazange abonise ngokucacileyo ukuba isixhobo sakhe sinciphise umngcipheko wesifo.
AKUKHO KUNCIPHISWA KOMNGCIPHEKO KUNYE NO-PHILIP MORRIS IQOS!
Ukuba uluvo lwe-FDA luyingcebiso kuphela kwaye aluyi kubuza umbuzo malunga nokuthengiswa okunokwenzeka kwemveliso kwiinyanga ezimbalwa, inyaniso ihleli kukuba izigqibo eziveziweyo zihlala zingalunganga. Enyanisweni, ngokutsho kwe-Federal Health Agency (FDA) advisory committee (i-FDA) edibene izolo Philip Morris International akufanele ivunyelwe ukuba ibango lokuba i-iQOS isixhobo sayo secuba eshushu sinokunciphisa umngcipheko wezifo ezinxulumene nokutshaya.
Le komiti icinga ukuba uPhilip Morris akakhange abonise ngokupheleleyo ukuba isixhobo sakhe siyawunciphisa umngcipheko wesifo. Kwakhona waligatya ibango lokuba ukusebenzisa esi sixhobo akuyongozi kangako kunokuqhubeka utshaya.
Ikomiti, nangona kunjalo, yamkele ibango likaPhilip Morris lokuba i-iQOS inciphisa ukuvezwa kwabasebenzisi bayo kwiikhemikhali ezinobungozi okanye ezinokuthi zibe yingozi kubantu abatshayayo abayeka ngokupheleleyo ukutshaya. Kodwa inkampani yecuba ayizange ibonise ukuba ukuncitshiswa koku kubhencwa kuphumele ngendlela enokwenzeka ngokusengqiqweni ngendlela enokulinganiswa nenkulu yokufa kwabantu.
Okwangoku, esi sibhengezo saba nefuthe elinamandla kwi-stock market Philip Morris elahlekelwe ngaphezu kwe-6% ngaphambi kokucima inxalenye yelahleko yayo kunye nokuthumela ukuhla kwe-2,1% kwi-108,28 yeedola kwi-17: 47 p.m. GMT kwiWall Street. Ukubona ukuba kwiinyanga ezizayo isixhobo siya kufumana isigunyaziso sokuthengisa eUnited States okanye hayi.
imvelaphi : Boursorama
